Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.

AIMS To investigate the effects of methotrexate (MTX) on the pharmacokinetics (PK) of CP-690,550, a novel Janus kinase (JAK) inhibitor in development as a therapy for rheumatoid arthritis (RA), to determine the effects of multiple doses of CP-690,550 on the PK of MTX, and to evaluate the short-term safety and tolerability of co-administration of CP-690,550 and MTX. METHODS This was a fixed-dose drug-drug interaction study. Twelve patients diagnosed with RA for at least 6 months were enrolled in a Phase I, open-label study of the PK of multiple doses of CP-690,550 (30 mg b.i.d.) and single doses of MTX (15-25 mg per week). RESULTS All patients completed the study and were evaluated for PK and safety. CP-690,550 exposure was not affected by co-administration with MTX; AUC(12) ratio (CP-690,550 + MTX/CP-690,550) was 103.06% [90% confidence interval (CI) 99.00, 107.29]. MTX exposure decreased by 10%; AUC(12) ratio (CP-690,550 + MTX/MTX) was 89.53% (90% CI 77.38, 103.57), which was not considered clinically significant. Co-administration of CP-690,550 and MTX was safe and well tolerated. There were no serious adverse events or withdrawals from the study and there was no trend in the incidence or severity of adverse events across treatments. CONCLUSIONS Co-administration of CP-690,550 and MTX was safe and well tolerated. There was no clinically significant effect on the PK profile of either drug. Therefore, dose adjustments should not be required when co-administering CP-690,550 and MTX.

[1]  Atlanta,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. , 2008, Arthritis and rheumatism.

[2]  F. Breedveld,et al.  Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial , 2009, Annals of the rheumatic diseases.

[3]  G. Chan,et al.  Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. , 2009, The Journal of investigative dermatology.

[4]  J. Johnston,et al.  Regulation of JAK3 expression and activation in human B cells and B cell malignancies. , 1995, Journal of immunology.

[5]  F. Breedveld,et al.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.

[6]  G. Panayi.  B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? , 2005, Rheumatology.

[7]  R. Yood,et al.  Guidelines for the management of rheumatoid arthritis: 2002 Update. , 2002, Arthritis and rheumatism.

[8]  Peter Lipsky,et al.  Cytokines and their role in lymphoid development, differentiation and homeostasis , 2002, Current opinion in allergy and clinical immunology.

[9]  A. Burls,et al.  A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. , 2003, Rheumatology.

[10]  C. Doré,et al.  A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. , 2005, Rheumatology.

[11]  J. Johnston,et al.  Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. , 1994, Science.

[12]  M. Hutmacher,et al.  Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  J. Johnston,et al.  Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7 , 1995, The Journal of experimental medicine.

[14]  John Han,et al.  Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. , 2006, Arthritis and rheumatism.

[15]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[16]  P. Tugwell,et al.  Generic quality-of-life assessment in rheumatoid arthritis. , 2007, The American journal of managed care.

[17]  A. Hassell,et al.  The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. , 2005, Rheumatology.

[18]  J. Johnston,et al.  Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Fox,et al.  Cells of the synovium in rheumatoid arthritis , 2007 .

[20]  D. M. van der Heijde,et al.  Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. , 2006, Arthritis and rheumatism.

[21]  J. Singh,et al.  Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. , 2008, The American journal of managed care.

[22]  G. Newsome.  Guidelines for the management of rheumatoid arthritis: 2002 update. , 2002, Journal of the American Academy of Nurse Practitioners.

[23]  S. Gabriel,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. , 2008, Arthritis and rheumatism.

[24]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[25]  Claudia Mauri,et al.  Cells of the synovium in rheumatoid arthritis , 2007 .

[26]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.